Friday, February 3, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Developing a Next Generation Q Fever Vaccine

by Global Biodefense Staff
January 21, 2015
Q Fever Coxiella burnetii bacteria

A recent review published in the journal Frontiers in Microbiology highlights key aspects of Q Fever, discussing the risk the disease poses to military personnel, recent advances in countermeasures and a strategic approach to provide a next-generation vaccine against Q Fever for the warfighter.

Q Fever represent a threat due to its low infectious dose and environmental stability. The causative agent, Coxiella burnetii, is found worldwide and can be spread via inhalational exposure to the bacteria.

While considered a potential bioterroism agent, the military is also concerned about natural exposures to Q Fever. In an analysis of U.S. troops deployed to an area of Iraq with known Q Fever outbreaks, 7.2 percent were suspected to have been naturally exposed to C. burnetii during the deployment.

In a more comprehensive study, deployed warfighters admitted to hospitals with fever and other non-specific symptoms were monitored to determine which pathogens may have caused the illness. Approximately 10 percent of these individuals tested positive for Q Fever.

As chronic cases of Q Fever are difficult to diagnose and treat with antibiotics, vaccination strategies have been considered a viable alternative for at-risk populations. Q-Vax is a formalin-inactivated whole cell vaccine that is currently being utilized in Australia, demonstrating that effective, vaccine-mediated protection is possible. However, this vaccine cannot be administered to individuals that have previously been exposed to C. burnetii, which can represent a large percentage of deployed forces.

Given such limitations, the Department of Defense desires a next-generation vaccine against Q Fever that could be administered to the warfighter regardless of their exposure history.

Read more at Frontiers in Microbiology:  Vaccination against Q fever for biodefense and public health indications

Source: DTRA, adapted.

Tags: Q FeverVaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC